Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery
From the National Multiple Sclerosis Society Case Conference Proceedings
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 12, 2022
- Accepted in final form September 12, 2022
- First Published November 10, 2022.
Author Disclosures
- Daniela A. Pimentel Maldonado, MD, MSCR,
- Robert Lisak, MD,
- Steven Galetta, MD,
- Laura Balcer, MD, MSCE,
- Thomas Varkey,
- Andrew Goodman, MD,
- Jennifer Graves, MD, PhD,
- Michael Racke, MD,
- Scott S. Zamvil, MD, PhD,
- Scott Newsome, DO*,
- Elliot M. Frohman, MD, PhD* and
- Teresa C. Frohman, MPAS, PA-C*
- Daniela A. Pimentel Maldonado, MD, MSCR,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Robert Lisak, MD,
1) Advisory Board Commercial: Argenx, ; Mallinckrodt, Takeda, Alivant, ANI, MedDay, Horizon ;2) Advisory Board non-profit: National Multiple Sclerosis ;Society, ;Michigan Chapter, Clinical Advisory Committee; Myasthenia ;Gravis ;Foundation of America, Clinical Advisory Committee; ;Guillain-Barre Syndrome/CIDP Foundation, International, ;Global Medical Advisory Commmittee
NONE
None
Section Editor for Neuroimmunology, Clinical ;Neuropharmacology, 2005-present; Editorial Board, ;Immunology Research, 1986-2021; Neuroimmunology Reports ;2020-present
NONE
International Neurology: A Clinical Approach, Blackwell, ;Oxford, 2009; 2017 (2nd edition) ;Neuroimmunology, Oxford University Press, 2019
NONE
1)GLG Consulting; Insight Consulting; Alpha Sites ;Consulting; Argenx; Clearview Consulting, Guidepoint ;Consulting; Jupiter Consulting; Dedham, Triangle ;Insights, Horizon Pharmaceuticals, ALI, Alivar,Takeda, ;COUR (Data Safety Monitoring Board) ; ;and ACTHar Gel, Takeda consulting on autoimmune ;neurologic disorders, Janssen consulting on S1P receptor ;modulators
NONE
Health Advisory Committee; National Multiple ;Sclerosis Society, Michigan Chapter, Board of Governors; ;Research Grants Committee and Centers of Excellence ;Committee of the Medical Advisory Committee of the ;GBS/CIDP Foundation, International; Grants Committee of ;the Myasthenia Gravis Foundation of America ended-2020
NONE
Alexion; Genentech, Novartis, ;Medimmune; Chugai, UCB/Ra Pharmaceuticals, Argenx, Takeda ;paid to Wayne State University for my participation in ;clinical trials ;MedDay as Chair of Adjudication Committee for study of ;biotin in progressive forms of MS
NINDS; 1R21NS118227-01; PI; 7/15/2020-06/30/2023
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Steven Galetta, MD,
None
NONE
None
(1) Neurology, Editorial Board; ; ;(2) Journal of Neuro-ophthalmology, Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Balcer, MD, MSCE,
Editor in Chief, Journal of Neuro-Ophthalmology, receive payments from the North American Neuro-Ophthalmology Society
NONE
None
Journal of Neuro-Ophthalmology, Editor-in-Chief, 2019-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Varkey,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew Goodman, MD,
IMCYSE
NONE
Received travel expenses and/or honoraria for lectures or ;educational activities not funded by industry from Americas Committee for Research and Treatment in MS; Guthy-Jackson Charitible Foundation; Race ;to Erase MS. ;Received travel expenses and/or honoraria for consuting ;from Genetech; Janssen: Lilly.
NONE
NONE
Royalties:
NONE
1 Adamas: consultant; SwanBio: consultant; Novartis: consultant; Janssen: consultant; Genentech:consultant; Lilly: consultant
NONE
NONE
NONE
1.Biogen-Idec:research support ;2.Genzyme-sanofi:research support;3. Novartis: research ;support 3.Atara; research support4 . Roche:research ;support
1. FUNDING AGENCY Mass Gen Hosp/NeuroNEXT (NINDS) Goodman (Site-PI NAME) Fox (PPI) ;DATES OF ACTIVE/PENDING AWARD 9/1/13-8/31/18 ANTIC ;TOTAL COSTS $151,880 PERCENT EFFORT 2% TITLE OF PROJECT (OR SUBPROJECT) A Randomized D-B, P-C ;Study to Evaluate the Safety, Tolerability & Activity of ;Ibudilast (MN-66) in Subjects with Progressive Multiple ;Sclerosis. ; ;2. FUNDING AGENCY John Hopkins University GRANT/CONTRACT NUMBER, (PI NAME) Andrew Goodman, MD ;DATES OF ACTIVE/PENDING AWARD : : 7/15/2011-3/31/2014 ANTIC TOTAL COSTS $0 PERCENT EFFORT ; 2% ;TITLE OF PROJECT (OR SUBPROJECT) A Randomized Controlled ;Trial of Vitamin D in Multiple Sclerosis ; ;3. UNIV/SUNY Buffalo:Establish NYS Multiple Sclerosis ;Consortium Currently Funded Grants/Contracts Andrew ;Goodman $0.00 $67,866.00 03/01/1995 10/31/2014 0% The ;goal of this study is to develop an ongoing, centralized, ;uniform database of MS patient information and specimens ;for member centers.
NONE
1. National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
Acorda Therapeutics, expert witness for plaintiff
- Jennifer Graves, MD, PhD,
Novartis, Genentech, Bayer
NONE
None
Assistant editor for Neurology 2020-2021 ;Associate editor for ACTN 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Octave ;2) Biogen ;3) EMD Serono ;4) Sanofi
NONE
NONE
1) National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Racke, MD,
None
NONE
None
Journal of Neuroimmunology, Editor-in-Chief, 2010-2020 ;Spouse has following editorial positions: ;Journal of Immunology- Section Editor ;Frontiers in Multiple Sclerosis and Neuroimmunology- ;Associate Editor ;Journal of Neuroimmunology-Deputy Editor- 2010-2020 ;Brain, Behavior, and Immunity-Editorial Board
NONE
NONE
Quest Diagnostics, Medical Director for Neurology, 2 years
NONE
NONE
NONE
NONE
Salary from Quest Diagnostics
Spouse has funding from NIH
NONE
None
Stock options from Quest Diagnostics
NONE
NONE
NONE
NONE
NONE
- Scott S. Zamvil, MD, PhD,
Dr. Zamvil has received honoraria for serving on Data Safety ;Monitoring Boards for MS trials conducted by Opexa, BioMS, ;Teva Pharmaceuticals, Inc. and Eli Lilly and Co. ;Foundation.
NONE
(1) Biogen - Speaker honoraria and advisory board meetings ;(2) Teva - Speaker honoraria and advisory board meetings ;(3) Alexion - Speaker honoraria and advisory board meetings ;(4) Novartis - Speaker honoraria and advisory board meetings
(1) Neurology, Neuroimmunology and Neuroinflammation, ;Deputy Editor, 2014-present
NONE
NONE
NONE
SSZ has served as a consultant to Biogen Idec, Teva ;Neuroscience, EMD-Serono, Genzyme, Novartis and Roche.
Advanced Health Media, 2009-present ;Biogen, 2009-present ;Alexion, 2019-present ;Viela Bio, 2020
NONE
NONE
(1) Biogen - speaker and advisory board meetings ;(2) Teva - speaker and advisory board meetings ;(3) Genentech - advisory board meeting ;(4) Novartis - advisory board meetings ;(5) Genzyme - advisory board meetings ;(6) Alexion - advisory board meeting
NIH RO1 AI131624-O1A1 ;NIH R21 NS10815990-01
NMSS RG 1701-26628 ;NMSS RG 1801-29861
Alexander M. and June L. Maisin Foundation, PI
NONE
NONE
NONE
NONE
NONE
NONE
- Scott Newsome, DO*,
Biogen Idec, scientific advisory board ;Genentech, scientific advisory board ;EMD Serono, scientific advisory board ;Bristol Myers Squibb, scientific advisory board ;Greenwich Biosciences, scientific advisory board ;Novartis, scientific advisory board ;Horizon Therapeutics, scientific advisory board ;medDay Pharmaceuticals, clinical adjudication committee ;member for a clinical trial
NONE
None
NONE
NONE
NONE
NONE
Autobahn
NONE
study lead PI for a Roche clinical trial
NONE
Biogen Idec; research support payed directly to my ;institution and not relevant to the submitted manuscript ;Genentech; research support payed directly to my ;institution and not relevant to the submitted manuscript ;Roche; research support payed directly to my ;institution and not relevant to the submitted manuscript
NONE
NONE
National Multiple Sclerosis Society ;Department of Defense ;Patient Centered Outcomes Research Institute ;The Stiff Person Syndrome Research Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Elliot M. Frohman, MD, PhD* and
None
NONE
Genzyme-Speaker fees Novartis-Speaker fees Alexion-Speaker fees Janssen-Speaker fees
J of Neurology-Editorial Board Frontiers in Neurology-Editorial Board J of the Neurological Sciences-Editorial Board Neuroimmunology Reports-Editorial Board
NONE
1. Up To Date: i). Internuclear ophthalmoparesis ii). Multiple Sclerosis: Symptom management 2) Cambridge University Press Optical Coherence Tomography in Neurological Diseases
NONE
NONE
Genzyme Novartis Alexion Janssen
NONE
NONE
NONE
NONE
NONE
National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Teresa C. Frohman, MPAS, PA-C*
spouse:Genzyme, Alexion, Novartis, JANSSEN- speaking and ;consulting
NONE
Spouse: Genzyme, Alexion, Novartis
self and spouse: ;Editor Neurology Reports ;Contributor: Up To Date ;NMSS Fellows Webinar Case Conference Proceedings
NONE
Self: Up-To-Date ; ;Spouse: Up-To-Date
NONE
Spouse: Genzyme, Alexion, Novartis, Janssen
Spouse:Genzyme, Alexion, Novartis, Janssen
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (D.A.P.M., S.N.), Johns Hopkins Hospital, Baltimore, MD; Department of Neurology (R.L.), Wayne State University, Detroit, MI; Departments of Neurology (S.G., L.B.), Population Health, and Ophthalmology, NYU Grossman School of Medicine; Department of Neurology (T.V.), Dell Medical School, The University of Texas at Austin; Department of Neurology (A.G.), University of Rochester, NY; Department of Neurosciences (J.G.), University of California at San Diego; Quest Diagnostics (M.R.), Secaucus, NJ; Department of Neurology and Program in Immunology (S.S.Z.), University of California San Francisco; and Distinguished Senior Fellows (Sabbatical) Neuroimmunology Laboratory of Professor Lawrence Steinman (E.M.F., T.C.F.), Stanford University School of Medicine, Palo Alto, CA.
- Correspondence
Dr. Frohman elliot.frohman{at}austin.utexas.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.